Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evogliptin SCHEMBL343846 | 0.81 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL30866226 | 0.81 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2298513 | 0.81 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL18331680 | 0.81 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL343847 | 0.81 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2491981 | 0.81 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2496606 | 0.81 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2491978 | 0.81 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493817 | 0.80 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493812 | 0.80 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2669266-B1 | Improved Method for Manufacturing Dipeptidyl Peptidase-IV Inhibitor and Intermediate | DONG A ST CO LTD (KR) | 2016-02-24 | — | — | EP | disclosed |
| US-8598347-B2 | Method for manufacturing dipeptidyl peptidase-IV inhibitor and intermediate | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2013-12-03 | — | — | US | disclosed |
| EP-2415754-A2 | IMPROVED METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | Dong-A Pharmaceutical Co., Ltd. (KR) | 2012-02-08 | — | — | EP | disclosed |
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DONG-A PHARMACEUTICAL. CO., LTD (KR) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016126-A1 | METHOD FOR MANUFACTURING DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND INTERMEDIATE | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3226/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.